Dr. Royce on Progress Being Made in HER2+ Positive Breast Cancer

Melanie E. Royce, MD, PhD
Published: Tuesday, Jan 31, 2017



Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

The most exciting part in the future is patient selection, she adds. What researchers are currently discovering are molecular tests for these patients to ensure they are being administered optimal therapy, Royce explains. Once these patients are determined, it may be appropriate to use more than 1 assay if it is necessary. 


Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

The most exciting part in the future is patient selection, she adds. What researchers are currently discovering are molecular tests for these patients to ensure they are being administered optimal therapy, Royce explains. Once these patients are determined, it may be appropriate to use more than 1 assay if it is necessary. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x